Welcome to our dedicated page for Elicio Therapeutics SEC filings (Ticker: ELTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Elicio Therapeutics filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company focused on cancer immunotherapies. Its disclosures cover common stock registered on The Nasdaq Capital Market, emerging growth company reporting status, operating and financial results, corporate updates, and material-event reports.
Recent filings also address capital-structure matters, including an at-the-market equity program tied to a Form S-3 registration statement, as well as Regulation FD and other event disclosures for ELI-002, AMPLIFY-7P, AMPLIFY-201, mKRAS-specific T cell response data, scientific publications, governance matters, shareholder voting topics, and risk-related clinical and regulatory updates.
Elicio Therapeutics, Inc. is a clinical-stage biotech focused on AMP-based cancer immunotherapies, led by ELI-002 7P for mKRAS-positive pancreatic and other solid tumors. For the six months ended June 30, 2026, it reported a net loss of $20.0 million, slightly lower than $21.8 million a year earlier, on operating expenses of $21.0 million. Cash and cash equivalents were $23.5 million, with total assets of $31.3 million and a long-term debt balance of about $9.5 million on a $10.0 million senior secured promissory note.
The Phase 2 AMPLIFY-7P trial in adjuvant mKRAS-driven PDAC did not meet its pre-specified primary disease-free survival endpoint in the intent-to-treat population, though management highlights early DFS separation during treatment, favorable safety, and stronger effects in certain subgroups to refine a planned Phase 3 strategy. Management discloses substantial doubt about the company’s ability to continue as a going concern, expecting its cash to fund operations only into the first quarter of 2027. To bolster liquidity, Elicio raised approximately $24.4 million via at-the-market equity programs in the first half of 2026 and a further $13.6 million in a July 2026 registered direct offering, but anticipates needing additional capital to advance trials and sustain operations.
Elicio Therapeutics, Inc. reported second quarter 2026 results and clinical updates focused on its lead KRAS-targeted immunotherapy ELI-002 7P. For the quarter ended June 30, 2026, net loss was $8.2 million compared with $10.6 million a year earlier, or $0.43 per share versus $0.66. Research and development expense was $6.8 million and general and administrative expense was $3.6 million. Cash and cash equivalents totaled $23.5 million on June 30, 2026, supported by $16.6 million in at-the-market proceeds year-to-date and a subsequent $15.0 million registered direct financing in July 2026; the company expects this cash to fund operations into the first quarter of 2027. Clinically, a Phase 2 AMPLIFY-7P trial in adjuvant pancreatic cancer did not meet its primary endpoint, while Elicio reported multiple complete responses in metastatic KRAS-mutant pancreatic cancer and plans a Phase 1 combination trial in metastatic disease anticipated to start in the fourth quarter of 2026.
Elicio Therapeutics, Inc. reported that Executive Vice President, Head of R&D and Chief Medical Officer Christopher Haqq received a grant of 64,643 stock options on July 16, 2026 at an exercise price of $3.20 per share, expiring on July 16, 2036. The options vest 50% on July 16, 2027 and 50% on July 16, 2028, subject to his continued service, and cover 64,643 shares of common stock.
Elicio Therapeutics, Inc. reported that Chief Scientific Officer Peter DeMuth received a grant of stock options covering 52,832 shares of common stock. The options have an exercise price of 3.2000 per share and expire on 2036-07-16. They vest 50% on July 16, 2027 and 50% on July 16, 2028, subject to his continued service, leaving him with 52,832 options outstanding after this grant.
Elicio Therapeutics, Inc. reported that Chief Strategy and Financial Officer Preetam Shah received a grant of stock options covering 60,833 shares of common stock at an exercise price of $3.20 per share. The options expire on July 16, 2036 and vest 50% on July 16, 2027 and 50% on July 16, 2028, subject to his continued service.
Elicio Therapeutics, Inc. granted CEO, President and Director Robert Connelly a stock option for 186,944 shares of common stock at an exercise price of 3.2000 per share on July 16, 2026, expiring July 16, 2036. The option vests 50% on July 16, 2027 and 50% on July 16, 2028, subject to his continued service, resulting in direct holdings of 186,944 options under this award.
Moti Investments LLC is reported as a significant shareholder of Elicio Therapeutics, Inc., with beneficial ownership of 1,408,892 shares of common stock, par value $0.01 per share. This position represents 6.1% of Elicio’s common stock class.
Moti Investments, organized in Saint Kitts and Nevis and based in Dubai, has sole voting power and sole dispositive power over all 1,408,892 shares, with no shared voting or dispositive power. The report is signed by Manager Kalpana H. Jogani, dated July 16, 2026.
Elicio Therapeutics ownership update: Knoll Capital Management, Fred Knoll and Gakasa Holdings amended their Schedule 13G/A to report beneficial ownership of 1,211,957 shares of Common Stock, representing 5.3% of the class. The filing shows shared voting and shared dispositive power for the same amount.
Elicio Therapeutics, Inc. is offering 4,380,313 shares of common stock in a registered offering priced at $3.43 per share (aggregate offering price $15,024,473.59). Delivery is expected on or about July 6, 2026.
The company expects net proceeds of approximately $13.6 million to fund a planned Phase 1 study of ELI-002 7P in metastatic mKRAS PDAC, advance its pipeline and platform, and for working capital and general corporate purposes. The prospectus supplement discloses AMPLIFY-7P Phase 2 topline results which did not meet the prespecified primary DFS endpoint in the intent-to-treat population, but post-hoc analyses indicated early DFS benefit and a stronger effect in the R0 resected subgroup; a Phase 3 strategy focused on R0 patients is planned, subject to financing.
Elicio Therapeutics, Inc. entered into a securities purchase agreement for a registered direct offering of 4,380,313 shares of common stock at $3.43 per share, for aggregate gross proceeds of about $15 million before fees and expenses. The offering is being conducted under Elicio’s effective Form S-3 shelf registration statement and is expected to close on or about July 6, 2026, subject to customary conditions.
The company agreed to a 30-day restriction on issuing additional common stock or equivalents after closing. Elicio intends to use net proceeds, together with existing cash and investments, primarily to fund planned Phase 1 development of ELI-002 7P in metastatic pancreatic ductal adenocarcinoma, its broader pipeline and platform, and for working capital and general corporate purposes.